Tagged with RMAC

Switzerland Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of melatonin for insomnia.  Neurim Pharmaceuticals is an Israeli company focused on CNS, with a second office in Switzerland. Could you…

Singapore Renaud Jonquieres, Vice President Asia-Pacific of bioMérieux Industry, enthusiastically conveys the company’s scope and significance in the Asia-Pacific region, the competitive landscape, as well as the key strategic objective to foster long-term growth. To begin, please provide a brief overview of bioMérieux’s history, including the scope that it encompasses and…

Chiesi Mario Muniz, general manager of Chiesi Mexico, explains how the affiliate looks at becoming a comprehensive solution provider in the neonatal field, highlights the dramatic consequences of the health budget cuts recently released by the government, and shows how empowering its employees has led the affiliate to recently win a…

Biomed CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you start by introducing Biomed to our international readers? We represent companies which are not present in Switzerland directly. Some companies…

Merck Asanga Halangoda, Director of Life Science at Merck Philippines, discusses the company’s impressive recent market performance, the importance of innovation in maintaining product pipeline, and the bright future of the affiliate’s role in the company’s emerging market portfolio. As an introduction to our readers, could you please give us an…

Slovakia Slovakia has been Europe’s fastest growing economy over the last ten years and the government has identified areas within life sciences as strategic centers for investment in the country. Slovakia has a lot to offer biopharma investors according to Robert Simoncic, head of the Slovak investment and trade development agency…

Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…

Pharma Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to expand PROBIOMED’s business within the region. Last time we met with you, you explained that PROBIOMED was following a three…

Pharma Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period of rapid growth.   2015 was a fantastic year for the company, the best yet, passing the USD two billion…

Pharma André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s business model, and ensuring that those affected with hepatitis C are able to receive treatment in Switzerland. A lot has…

Pharma A native of Serbia, Aleksandar Ciric provides his first impressions of the Slovak market and business atmosphere, emphasizing the transparency and market accessibility. His current priority at Novo Nordisk is to develop the local organization by developing its people in order to maintain a competitive edge. After eight months in Slovakia,…

Manufacturing James Byrne, VP Site for Ipsen Manufacturing Ireland, discusses the strategic importance of the Ireland site as the sole provider of peptides for products generating over 50 percent of Ipsen’s global revenues; his strategy for attracting and retaining the best talent; and his thoughts on the impact of new manufacturing…